ALGS
$1.06
Aligos Therapeutics
($.04)
(3.64%)
ALGS
Earnings Whisper ®
N/A
3rd Quarter September 2022
Consensus:  ($0.57)
Revenue:  $0.75 Mil
Thursday
Nov 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALGS reports earnings?
Beat
Meet
Miss

Where is ALGS's stock price going from here?
Up
Flat
Down
Stock chart of ALGS
Analysts
Summary of analysts' recommendations for ALGS
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.